Table 3.
Overall prevalence of doravirine-associated resistance, intermediate and high-level resistance levels with specific mutations among ART-naïve and individuals with virologic failure on ART
| Resistance levels | Total N = 1473 (%) | ART-naïve N = 1261 (%) | Individuals with VF on ART N = 212 (%) | P values |
|---|---|---|---|---|
| Overall resistance | 181 (12.3) | 139 (11.0) | 42 (19.8) | <0.01 |
| Intermediate | 135 (9.2) | 106 (8.4) | 29 (13.7) | <0.01 |
| High-level resistance | 46 (3.1) | 33 (2.6) | 13 (6.1) | <0.01 |
| Specific intermediate mutations | ||||
| V106M | 12 (0.8) | 5 (0.4) | 7 (3.3) | <0.01 |
| Y188F | 2 (0.14) | 0 | 2(0.9) | NA |
| Specific high-level mutations | ||||
| V106A | 2 (0.14) | 0 | 2 (0.9) | NA |
| Y188L | 2 (0.14) | 0 | 2 (0.9) | NA |
| G190E | 33 (2.2) | 30 (2.4) | 3 (1.4) | 0.36 |
| F227C | 1(0.07) | 0 | 1(0.5) | NA |
| F227L | 2 (0.14) | 1 (0.08) | 1(0.5) | 0.131 |
| M230L | 2(0.14) | 0 | 2 (0.9) | NA |
| Y318F | 1(0.07) | 0 | 1 (0.5) | NA |
NOTE: P values from comparison of proportions of mutations among ART-naïve and individuals with VF on ART. All mutations reported among individuals with VF on ART were from individuals failing NNRTI with at least one major EFV/NVP-associated resistance mutation. Note that none of the individuals had DOR-associated resistance in the absence of EFV/NVP resistance associated mutations.
ART, antiretroviral therapy; NA, not applicable; VF, virologic failure.